SMP-100 / Chengdu Kelingyuan Pharma, ConSynance 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SMP-100 / Chengdu Kelingyuan Pharma, ConSynance
ChiCTR2300073608: Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SMP-100 in Chinese Healthy Volunteers

Completed
1
40
 
6 subjects were given a single low-dose of SMP-100 tablets and 2 were given placebos ;6 subjects were given a single medium-dose of SMP-100 tablets and 2 were given placebos ;6 subjects were given a single high-dose of SMP-100 tablets and 2 were given a placebos ;6 subjects were given low-dose SMP-100 tablets for 7 consecutive days, and 2 were given placebos ;6 subjects were given high-dose SMP-100 tablets for 7 consecutive days, and 2 were given placebos
Wuxi People's Hospital; SciMount Therapeutics (Shenzhen) Co., Ltd., Sponsor
IBS
 
 

Download Options